Dupilumab in the therapy of severe allergic asthma in a patient with atopic dermatitis Dupilumab in the therapy of severe allergic asthma in a patient with atopic dermatitis
Abstract
Severe persistently uncontrolled asthma is associated with reduced quality of life. Add-on treatment with biologics meant a reversal in severe asthma therapy as it leads to better quality of life, reduced risk of exacerbations, better control of asthma symptoms and reduction of a dose of long-term oral glucocorticoid therapy.
Since 2019 anti-IL-4 receptor alpha subunit antibody dupilumab has been available in the Czech Republic. It blocks the effect of interleukin-4 and interleukin-13, which play an important role in type 2 inflammation.
In this case we present a patient with severe eosinophilic asthma and atopic dermatitis who has been treated with dupilumab. This therapy has led to a reduction of asthma exacerbations, amelioration of atopic dermatitis and better quality of life.